Video

Dr. Sledge Discusses Lasting Issues in Breast Cancer

George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses the lasting issues in the treatment of breast cancer.

George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses the lasting issues in the treatment of breast cancer.

Though the mechanisms of resistance have been identified for several types of breast cancer, inhibiting the mechanism is difficult. In the case of a patient who is resistant to an aromatase inhibitor, everolimus (an mTOR inhibitor) allows resistance to be overcome, as mTOR is a common pathway. This issue is relatively straightforward, Sledge says, as the current knowledge of resistance just needs to be applied.

Estrogen receptor positive disease that lies dormant for 5-10 years still presents problems for physicians and researchers. Questions remain as to how dormant tumors can be identified and treated.

Finally, in the treatment of highly-aggressive disease such as triple-negative breast cancer, an obstacle exists as to what non-kinase-based approaches can be applied to achieve favorable results.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine